文献速递胸部肿瘤

小细胞肺癌的临床见解:肿瘤异质性、诊断、治疗与未来方向

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.
PubMed 文献 · CA Cancer J Clin · 2023-06-17

小细胞肺癌(SCLC)生长快、转移早,与烟草致癌物密切相关,多数具神经内分泌特征但部分缺如。基因组 profiling 显示 TP53 和 RB1 几乎普遍失活、突变负荷高。仅少数患者可手术并需辅助铂-依托泊苷化疗;局限期标准为胸部放疗联合同步铂-依托泊苷化疗,广泛期采用铂-依托泊苷联合抗 PD-L1 免疫治疗。尽管初始对铂类敏感,但耐药导致缓解短暂。分子亚型分类的重定义有望揭示治疗脆弱性。

要点

  • SCLC 与烟草强相关,TP53 和 RB1 几乎普遍失活,突变负荷高。
  • 仅少数患者适合根治性手术,需辅助铂-依托泊苷化疗。
  • 局限期标准为胸部放疗联合同步铂-依托泊苷化疗;广泛期为铂-依托泊苷联合抗 PD-L1 免疫治疗。

核心结论

  • SCLC 分子亚型分类的重定义有潜力揭示独特治疗脆弱性,整合新发现与现有知识可能带来患者诊疗的空前进步。

研究设计与样本

  • 综述:总结 SCLC 多学科临床方法,重点关注近期研究进展如何加速临床开发。

主要发现

  • SCLC 生长快、转移能力高,与烟草致癌物有强流行病学和生物学联系。
  • 多数 SCLC 显示神经内分泌特征,但重要亚群缺乏这些特征。
  • 基因组分析显示遗传不稳定性、TP53 和 RB1 几乎普遍失活及高突变负荷。
  • 因早期转移,仅小部分患者适合根治性肺切除,这些个体需辅助铂-依托泊苷化疗。
  • SCLC 初始对铂类化疗非常敏感,但耐药导致缓解短暂。

关键数值与推荐

  • 局限期标准治疗包括胸部放疗和同步铂-依托泊苷化疗。
  • 转移性(广泛期)疾病采用铂-依托泊苷化疗联合抗程序性死亡配体1单克隆抗体免疫治疗。

临床怎么用

  • 绝大多数患者目前接受放化疗联合或不联合免疫治疗。
  • 适合根治性手术的小部分患者需辅助铂-依托泊苷化疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit neuroendocrine features, an important subset of tumors lacks these properties. Genomic profiling of SCLC reveals genetic instability, almost universal inactivation of the tumor suppressor genes TP53 and RB1, and a high mutation burden. Because of early metastasis, only a small fraction of patients are amenable to curative-intent lung resection, and these individuals require adjuvant platinum-etoposide chemotherapy. Therefore, the vast majority of patients are currently being treated with chemoradiation with or without immunotherapy. In patients with disease confined to the chest, standard therapy includes thoracic radiotherapy and concurrent platinum-etoposide chemotherapy. Patients with metastatic (extensive-stage) disease are treated with a combination of platinum-etoposide chemotherapy plus immunotherapy with an anti-programmed death-ligand 1 monoclonal antibody. Although SCLC is initially very responsive to platinum-based chemotherapy, these responses are transient because of the development of drug resistance. In recent years, the authors have witnessed an accelerating pace of biologic insights into the disease, leading to the redefinition of the SCLC classification scheme. This emerging knowledge of SCLC molecular subtypes has the potential to define unique therapeutic vulnerabilities. Synthesizing these new discoveries with the current knowledge of SCLC biology and clinical management may lead to unprecedented advances in SCLC patient care. Here, the authors present an overview of multimodal clinical approaches in SCLC, with a special focus on illuminating how recent advancements in SCLC research could accelerate clinical development.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Megyesfalvi Z, Gay CM, Popper H, et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023. PMID: 37329269. doi:10.3322/caac.21785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。